These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11818471)

  • 41. [Analytic and integrative perspectives for HIV vaccine design].
    Yamamoto H
    Uirusu; 2013; 63(2):219-32. PubMed ID: 25366056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is there any room for therapeutic vaccination against the HIV-1/AIDS?
    Iglesias E
    Hum Vaccin Immunother; 2013 Jul; 9(7):1539-44. PubMed ID: 23571171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current progress in the development of HIV vaccines.
    Spearman P
    Curr Pharm Des; 2006; 12(9):1147-67. PubMed ID: 16515492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.
    Heeney JL
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S53-64. PubMed ID: 15285705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human immunodeficiency virus: scientific challenges impeding candidate vaccines.
    Idemyor V
    HIV Clin Trials; 2003; 4(6):421-4. PubMed ID: 14628286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
    Haut LH; Ertl HC
    J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
    Sekaly RP
    J Exp Med; 2008 Jan; 205(1):7-12. PubMed ID: 18195078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Status of vaccine research and development of vaccines for HIV-1.
    Safrit JT; Fast PE; Gieber L; Kuipers H; Dean HJ; Koff WC
    Vaccine; 2016 Jun; 34(26):2921-2925. PubMed ID: 26993335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Some statistical issues in HIV vaccine trials.
    Rida WN; Lawrence DN
    Stat Med; 1994 Oct 15-30; 13(19-20):2155-77. PubMed ID: 7846417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV vaccine fails in phase 3 trial.
    McCarthy M
    Lancet; 2003 Mar; 361(9359):755-6. PubMed ID: 12620743
    [No Abstract]   [Full Text] [Related]  

  • 51. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary.
    Rida W; Fast P; Hoff R; Fleming T
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):195-203. PubMed ID: 9390572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies.
    Chin'ombe N; Ruhanya V
    Pan Afr Med J; 2015; 20():386. PubMed ID: 26185576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV preventive vaccines. Progress to date.
    Esparza J; Osmanov S; Heyward WL
    Drugs; 1995 Nov; 50(5):792-804. PubMed ID: 8586027
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Theory for prophylactic AIDS vaccine development].
    Nomura T; Matano T
    Uirusu; 2009 Dec; 59(2):267-75. PubMed ID: 20218335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toward an AIDS vaccine.
    Walker BD; Burton DR
    Science; 2008 May; 320(5877):760-4. PubMed ID: 18467582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 prophylactic vaccine trials in Thailand.
    Pitisuttithum P
    Curr HIV Res; 2005 Jan; 3(1):17-30. PubMed ID: 15638720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?
    Esparza J; Bhamarapravati N
    Lancet; 2000 Jun; 355(9220):2061-6. PubMed ID: 10885368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?
    Brown SA; Hurwitz JL; Zhan X; Doherty PC; Slobod KS
    Curr Drug Targets Infect Disord; 2005 Jun; 5(2):113-9. PubMed ID: 15975017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imperfect vaccines and herd immunity to HIV.
    McLean AR; Blower SM
    Proc Biol Sci; 1993 Jul; 253(1336):9-13. PubMed ID: 8396781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development.
    Marovich MA
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S99-104. PubMed ID: 15285709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.